Browsing Tag
Sanofi
64 posts
HLN share price firms as Sensodyne and Centrum drive Haleon’s 2026 organic growth recovery
Sensodyne grows 8%. Centrum targets GLP-1 users. The £500m buyback erases shares at sub-340p. Haleon's recovery hinges on Q2 cold and flu normalising.
Gujarat Themis Biosyn (GUJTHEM) bets on global branded generics with €158m Sanofi portfolio deal
Find out how Gujarat Themis Biosyn’s €158m Sanofi portfolio deal could reshape its global anti-infective growth strategy.
What new Dupilumab data suggest about long-term immune control in allergic disease at Regeneron Pharmaceuticals
New Dupilumab analyses highlight immune modulation claims. Read how Regeneron Pharmaceuticals is testing durability, reimbursement logic, and long-term strategy.
EYLEA HD and DUPIXENT anchor Regeneron’s 2026 growth plan amid clinical pipeline acceleration
Find out how Regeneron’s 18 new Phase III trials and four FDA approval targets in 2026 aim to reshape growth beyond DUPIXENT and EYLEA. Read the full story.
Sanofi bets on dosing discipline over rapid onset with amlitelimab’s Phase 3 readout
Sanofi moves amlitelimab toward global filings. Find out what the Phase 3 data mean for investors, competitors, and the dermatology biologics market.
Biggest pharma deals of 2025: How $70bn in M&A reshaped global drug strategy
Find out how Johnson & Johnson, Novartis, and Sanofi led the $70B pharma M&A wave in 2025, reshaping drug development strategy and investor confidence.
Sanofi bets $2.2bn on Dynavax to expand adult vaccine pipeline with hepatitis B and shingles focus
Find out how Sanofi’s $2.2B Dynavax buyout could reshape its adult vaccine strategy with HEPLISAV-B and a new shingles candidate in development.
Can GSK’s Exdensur transform asthma biologics with just two doses per year?
GSK’s Exdensur is now FDA approved as the first biannual biologic for severe asthma. Explore what this means for rivals, payers, and global strategy.
Sanofi invests up to $1bn in South Korean biotech ADEL to advance tau-based Alzheimer’s therapy
Sanofi has signed an up to $1 billion Alzheimer’s drug deal with South Korean biotech ADEL. Find out what the tau targeting strategy means for investors and patients.
Dupixent keeps winning trials—but can it survive the real battle with payers?
Explore how payer dynamics and pricing strategy may pose the biggest challenge for Dupixent’s growth, beyond clinical trials or biologic competitors.